… MEK combinations. We observed enhanced antitumor efficacy for RAF dimer and MEK inhibitor
… phospho-ERK blockade in enhancing the antitumor activity in the K-RAS mutant models. …

… , we demonstrate that the addition of the MEK inhibitor trametinib significantly improves the
antitumor effect of the BRAF inhibitor dabrafenib and two modes of immunotherapy, ACT and …

… useful to stratify patients enrolled in clinical trials of MEK inhibitors (10). We sought to address
whether MEK inhibition might have therapeutic value in breast cancer through evaluation …

… potent antitumor activity of combined therapy with PI3K/mTOR inhibitors and MEK inhibitors
… We showed impressive activity of this regimen in the RAS-driven melanoma model. Based …

… Here we propose a combination of MEK inhibitor binimetinib with metformin as a promising
therapy against human melanoma cells in vitro, including BRAF -mutated A375, Mel Z, and …

… antitumor efficacy of combined BET and MEK inhibition utilizing I-BET726, a prototype BET
inhibitor … As shown in Table 1, BET/MEK inhibition demonstrated synergy in 21 of 22 cases, …

Purpose Metformin, widely used as antidiabetic drug, showed antitumoral effects expecially
in combination with chemotherapy. Our group recently has demonstrated that metformin and …

… The data presented in this study demonstrated that MEK inhibition determines a strong
antitumor activity against the more tumorigenic metastatic melanoma cells expanded in vitro as …

… in vivo anti-tumor activity of treatment with selective MEK inhibitor pimasertib plus the mTOR
… here a significant cooperative antitumor activity when a dual inhibitor of PI3Ki/mTOR (…

… MEK inhibition promotes an increase in FOXO1 and FOXO3a protein levels and higher
transcriptional activity … The dual molecular targeted therapy for HDAC and MEK may be promising …